जहानाबाद, अप्रैल 18 -- जहानाबाद, निज प्रतिनिधि। जिले के विभिन्न सड़क मार्गों पर यातायात पुलिस और विभिन्न थानों की पुलिस के द्वारा चलाए जा रहे वाहन जांच अभियान के दौरान शुक्रवार की रात तक कई लोग नियम का... Read More
जहानाबाद, अप्रैल 18 -- करपी, निज संवाददाता। अग्निशमन सेवा सप्ताह के तहत शनिवार को अग्निशमन विभाग के द्वारा करपी पंचायत में व्यापक जागरूकता कार्यक्रम और मॉकड्रिल का आयोजन किया गया। जिला अग्निशमन पदाधिक... Read More
Singapore, April 18 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combi... Read More
Singapore, April 18 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the p... Read More
Singapore, April 18 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-98650... Read More
Singapore, April 18 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemother... Read More
Singapore, April 18 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safe... Read More
Singapore, April 18 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) ... Read More
Singapore, April 18 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig ... Read More
Singapore, April 18 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig ... Read More